Dou Y, et al. - Given the high patient-treatment burden and limited response rate related to chronic HBV (CHB) treatment with pegylated IFNα (PEG-IFN), researchers sought biomarkers that could predict response to PEG-IFN. Fifteen healthy controls, 15 acute self-limited HBV, 60 CHB patients, and 94 HBeAg+ CHB patients at week 0 and week 12 of a 52-week PEG-IFN treatment were evaluated for serum soluble CD14 (sCD14) levels. Receiver operating characteristic curves suggested a potential utility of fold change in sCD14 levels following 12-week treatment as a stopping rule to select patients at week 12 who may not benefit from further PEG-IFN treatment.